CS99 - I tend to agree with the #3 explanation. The only part I would wonder about is the fact that DM stated (I think the December webcast but sometime around then) that there were no more embargos. As long as he wasn't splitting hairs between the words embargo and agreement to deceive, which I hope he wasn't, I would think that at that time, RVX was free to release the eGFR data. They could maybe have a new embargo or agreement in place due to a conference or publication entered into since but it would seem that they were free to release at that time. If so, it was the company's choice to not release the data then which I hope means that maybe they wanted to withhold it until a more opportune (better aligned conference or such) time to release it. Maybe there was a compromise there. When DM was urged to withhold all data until maybe March or so and he scoffed at it (at AGM), maybe it was agreed to withhold this data until then. Hopefully, the data is very good and another BT follows for CKD. 

3. eGFR was improved but they are keeping quiet about despite the impact on share value. The only reason I can think of here is that it is going to be presented at a meeting or published in a paper soon and there is a prior agreement with investigators not to go public before then and/or an embargo imposed by the journal or congress.